Table 1.
Patient characteristics
| Characteristics | Number of patients n = 36, n (%) |
|---|---|
| Age (years) | |
| Median | 54 |
| Range | (15–79) |
| Gender | |
| Male | 14 (39%) |
| Female | 22 (61%) |
| Race | |
| White/Caucasian | 28 (78%) |
| Black/African-America | 4 (11%) |
| Other | 4 (11%) |
| Smoking | |
| Active or history of smoking | 18 (50%) |
| Never smoker | 18 (50%) |
| ECOG performance status | |
| 0 | 1 (3%) |
| 1 | 30 (83%) |
| 2 | 5 (14%) |
| Tumor type | |
| Head and neck squamous cell carcinoma | 10 (28%) |
| Cervical cancer | 10 (28%) |
| Thyroid follicular carcinoma | 4 (11%) |
| Breast cancer | 3 (8%) |
| Pancreatic cancer | 3 (8%) |
| Salivary glands cancer | 2 (6%) |
| Bladder urothelial carcinoma | 2 (6%) |
| Sarcoma | 1 (3%) |
| Vulvar cancer | 1 (3%) |
| Squamous cell carcinoma of the skin | 1 (3%) |
| Number of prior systemic therapies | |
| Median | 3 |
| Range | 1–10 |
| Prior systemic treatment with anti-EGFR | 8 (22%) |
| Prior systemic treatment with anti-VEGF | 9 (25%) |
| Prior systemic treatment with anti-EGFR and anti-VEGF (sequential) | 2 (6%) |